[Irinotecan in combination for colon cancer]

Area of Science:

• Oncology
• Medical Oncology
• Gastrointestinal Oncology

Background:

• Metastatic colorectal cancer (mCRC) treatment often involves 5-fluorouracil (5FU) and leucovorin.
• Irinotecan monotherapy shows efficacy in 5FU-resistant mCRC.
• Combining irinotecan with standard chemotherapy requires careful evaluation.

Purpose of the Study:

• To evaluate the efficacy and safety of irinotecan in combination with 5FU-based regimens for metastatic colorectal cancer.
• To explore different combination strategies, including concurrent and alternating schedules.
• To assess the potential of irinotecan in combination with other agents like oxaliplatin and mitomycin C.

Main Methods:

• Clinical trials investigating concurrent administration of irinotecan with leucovorin and 5FU (de Gramont regimen).
• Studies evaluating alternating schedules of 5FU/leucovorin and irinotecan.
• Combination studies of irinotecan with mitomycin C and oxaliplatin.

Main Results:

• Concurrent irinotecan with LV5FU2 (de Gramont regimen) demonstrates good tolerance and strong efficacy, leading to its development as a first-line treatment.
• Alternating schedules of 5FU/leucovorin and irinotecan show encouraging results, with response rates over 30% and median survival exceeding 16 months.
• Combinations of irinotecan with mitomycin C or oxaliplatin yield high objective response rates and good tolerability.

Conclusions:

• Irinotecan is a valuable agent in metastatic colorectal cancer treatment, particularly in combination regimens.
• Combination therapies involving irinotecan, 5FU, and leucovorin offer significant efficacy and improved patient tolerance.
• Further development of irinotecan-based combinations is warranted for first-line mCRC treatment.